Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 9;105(7):1835–1844. doi: 10.3324/haematol.2018.212589

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

The effect of minihepcidin on complete blood count and splenomegaly in Hbb^th1/th2-BMC mice. Administration of a low dose of minihepcidin (MH_L) (2.625 mg/kg) or a high-dose (MH_H) (5.25 mg/kg) to Hbb^th1/th2-BMC mice resulted in dose-dependent increases in (A) red blood cell (RBC) count and (B) hemoglobin (Hb) concentration and decreases in (C) reticulocyte (RETIC) count and (D) spleen weight. Bars represent the standard deviation. ****P≤0.001, **P≤0.01. (E) Minihepcidin administration also decreased hemichrome formation. (F) Flow cytometry studies of bone marrow and spleen erythroid populations of Hbb^th1/th2-BMC mice treated with MH_H showed reduced levels of reactive oxygen species. BM: bone marrow; ROS: reactive oxygen species.